Scientists at St. Jude Children’s Research Hospital are investigating the inherited genetics of childhood leukemia and how particular gene variations can affect treatment outcomes.
The work was published as an advance online publication this week in the Journal of the National Cancer Institute.
Minimal residual disease (MRD) checks for the presence of minute numbers of cancer cells after induction therapy, the first stage of ALL treatment. MRD is one of the strongest predictors of relapse risk for young ALL patients.
We know there is substantial variability in the way patients respond to ALL therapy. Certain mutations in leukemia cells are associated with drug response, but they certainly do not explain the full spectrum of the observed variability. This is when we realize we need to look at inherited genetic variants as well.”
Jun J. Yang, Ph.D, Study Corresponding Author, Pharmaceutical Sciences and Oncology,St. Jude Children’s Research Hospital
This cohort was large enough for the scientists to look for associations between the inherited genetics and end-of-induction MRD levels for 863,370 single nucleotide polymorphisms.
Results of the study showed that an inherited GATA3 variant strongly influenced how patients responded to therapy.
This variant is also associated with relapse. GATA3 is known by scientists to encode a crucial transcription factor for the development and differentiation of T cells.
“This variant isn’t completely new to us; we’ve previously found it to be associated with susceptibility to Philadelphia chromosome-like ALL, a rare but high-risk subtype,” Yang said.
“These new findings about the relationship between the GATA3 variant and MRD solidify the potential utility of inherited variants in how we assess newly diagnosed patients for risk-stratified therapy.”